Overview

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Pa

Status:
Completed

Trial end date:
2005-03-01

Target enrollment:

Participant gender:

Summary

This clinical pilot study will test the hypothesis that systemic low-dose IL-2 therapy significantly enhances the immunologic efficacy of a vaccine comprising melanoma peptides plus GM-CSF-in-adjuvant.

Phase:

Phase 2

Details

Lead Sponsor:

University of Virginia

Treatments:

Interleukin-2
Vaccines